Grants and Contributions:
Title:
Development of Novel Apelin Analog Drugs for Treatment of Cardiovascular Diseases
Agreement Number:
980844
Agreement Value:
$295,500.00
Agreement Date:
Nov 1, 2021 - Mar 31, 2024
Description:
PEARKO Therapeutics has been developing ApelinPlus (apelin analog) which can be a treatment for cardiovascular diseases. Currently, we are conducting preclinical testing of ApelinPlus, establishing required procedures, and preparing for regulatory filings with Health Canada, the Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6R 3A5
Reference Number:
172-2021-2022-Q3-980844
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
824764641
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 122 days.
Amendment Date
Dec 19, 2022
Recipient's Legal Name:
PEARKO Therapeutics Inc.
Federal Riding Name:
Edmonton Riverbend
Federal Riding Number:
48018
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: